SCHEMBL7014368

SCHEMBL7014368

OC(=S)CCc1cc2cc(Cl)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.57
SIRT1 Q96EB6 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.48
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
MEN1 O00255 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
DAO P14920 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
CYP19A1 P11511 1/20 0.44
FFAR1 O14842 5/20 0.43
PPARG P37231 2/20 0.41
F11 P03951 1/20 0.40
PYGL P06737 1/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014953 0.88 DAO (0.44) LOXL2SIRT1SMN1; SMN2DAOALDH1A1
SCHEMBL1500849 0.80 LOXL2 (0.64) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL7014365 0.80 SIRT1 (0.60) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL866136 0.79 LOXL2 (0.72) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL30222912 0.79 SIRT1 (0.58) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL10593440 0.77 SIRT1 (0.56) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL4740651 0.76 LOXL2 (0.68) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL2056276 0.76 LOXL2 (0.68) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL5097277 0.74 SIRT1 (0.74) LOXL2SIRT1SMN1; SMN2F7F3
SCHEMBL11174142 0.73 LOXL2 (0.68) LOXL2SIRT1SMN1; SMN2F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1302462-A1 SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof SULT1E1, RRS1, SHH LOXL2 2384/4885SIRT1 2618/4885SMN1; SMN2 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.